SWX:ROGPharmaceuticals
Roche (SWX:ROG) Valuation in Focus After Positive MS and Lupus Trial Results Energize Pipeline Prospects
Roche Holding (SWX:ROG) shares traded actively after the company announced that its experimental therapy, fenebrutinib, reached primary goals in Phase III trials for relapsing and primary progressive multiple sclerosis. This strengthens its neurology pipeline.
At the same time, Roche reported that Gazyva achieved clinically meaningful success in a pivotal study for systemic lupus erythematosus. These milestones could open new market opportunities and elevate Roche's growth profile in the...